Semaglutide vs Tirzepatide
Updated 6 sources
Key differences
- 1SURMOUNT-5 tested them head to head (751 adults, 72 weeks, open label): tirzepatide averaged 20.2% weight loss vs 13.7% for semaglutide, and 18.4 vs 13.0 cm off the waist.
- 2There is no validated dose conversion between them. Switchers restart tirzepatide low and titrate up.
- 3Guides say switch from one to the other, never take both.
- 4Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 only. Online shorthand calls them GLP-2 and GLP-1 for that reason.
- 5SURMOUNT-5 (751 adults without diabetes, 72 weeks, open label, max tolerated doses): weight fell 20.2% on tirzepatide vs 13.7% on semaglutide 1.7 or 2.4 mg.
- 6In SURMOUNT-5, 64.6% on tirzepatide lost at least 15% vs 40.1% on semaglutide; waist shrank 18.4 cm vs 13.0 cm.
- 7SURPASS-2 (type 2 diabetes, 40 weeks): HbA1c fell 2.0, 2.2 and 2.3 points on tirzepatide 5, 10 and 15 mg vs 1.9 on semaglutide 1 mg.
- 8Do not take them together. The tirzepatide label says co-use with other GLP-1 drugs is not recommended.
Side by side
Facts from each record, in the same words as their own pages.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
6 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study2
- SURMOUNT-5 journal scanAmerican College of Cardiology · checked Oct 23, 2026
- Lilly SURMOUNT-5 releaseDrugs.com · checked Oct 23, 2026
Regulatory4
- Mounjaro and Mounjaro KwikPen label, rev. 8/2026DailyMed · checked Oct 23, 2026
- Ozempic Prescribing Information (rev. 01/2025)FDA · checked Oct 23, 2026
- Wegovy injection and tablets label (SPL v19, Jun 30 2026)DailyMed · checked Oct 23, 2026
- Zepbound Prescribing Information, rev. 04/2026FDA · checked Oct 23, 2026